The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative .

Detailed Description
-----------------
Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative. HA contents 15μg/0.5ml per dose includ H1N1、H3N2 and B. Inactivated Split Influenza Vaccine was manufactured by Sanofi Pasteur HA contents 15μg/0.5ml per dose includ H1N1、H3N2 and B. This is a randomized, blind phase 3 clinical trial. Total 1200 adults (above ages 36 months ) were selected, randomized to two groups [Influenza Virus Vaccine (Split Virion, Inactivated) and Inactivated Split Influenza Vaccine , each group n=600], adults in each group will be vaccinated with one dose of either Influenza Virus Vaccine (Split Virion, Inactivated) or Sanof IVV respectively.

Official Title
-----------------
The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: Influenza Virus Vaccine
* Biological: Influenza Virus Vaccine(contains Preservative)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females, age above 36 months ; Adults, parent(s) or guardians are able to understand and sign informed consent for participation; Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions; Infants no vaccinated with influenza or other preventive biologicals in recent 7 days; Axillary temperature ≤37℃. Exclusion Criteria: Have medical record of participants or their family on allergy and egg, convulsion, falling sickness, encephalopathy and psychopathy; Low platelet or bleeding disorder do not allow vaccination into the muscle; Have damaged or lower immunological function; Received blood, plasma or immunoglobulin treatment since birth; Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome ); Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.

Ages Eligible for Study
-----------------
Minimum Age: 36 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Influenza Virus Vaccine<br>Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections | Biological: Influenza Virus Vaccine<br>* Influenza Virus Vaccine 0.5ml intramuscular injections<br>Biological: Influenza Virus Vaccine(contains Preservative)<br>* Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections<br>* Other names: Vaxigrip;|
| Experimental: Influenza Virus Vaccine(Preservative)<br>Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections | Biological: Influenza Virus Vaccine<br>* Influenza Virus Vaccine 0.5ml intramuscular injections<br>Biological: Influenza Virus Vaccine(contains Preservative)<br>* Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections<br>* Other names: Vaxigrip;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) |  | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Influenza Virus Vaccine (Split Virion, Inactivated), Influenza